Adipogen/BMS-5/SYN-1024-M010/10 mg
商品编号：
SYN-1024-M010
品牌：
Adipogen Inc
市场价：
¥3880.00
美元价：
2328.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | BMS5 |
| Product Type | Chemical |
| Properties | |
| Formula | C17H14Cl2F2N4OS |
| MW | 431.3 |
| CAS | 1338247-35-0 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: LIMK1 - LIMK2 | Kinase Group: TKL | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | IVUGBSGLHRJSSP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Kinases, such as LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LMK1 has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has been found to limit migration of human fibrosarcoma cells. Thus, the inhibition of LIMK1 and/or LIMK2 enzymes have been suggested as targets for treating cancer, including reduction or prevention of metastasis. BMS-5 is a potent inhibitor of the LIM kinase. It has IC(50) values of 7nM and 8nM for LIMK1 and LIMK2 respectively. LIMK1/2 activity was measured via TCA precipitation assay using a biotinylated ADF (actin depolymization factor) as the protein substrate and the kinase domains of LIMK1 and LIMK2 as the enzyme sources in the presence of 1µM ATP.
Product References
- Phenyl-substituted pyrimidine compounds useful as kinase inhibitors: S.T. Wrobelski, et al.; WO2006084017 (2006)
- Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton: E. Mashiach-Farkash, et al.; Oncotarget 3, 629 (2012)
- LIM kinase regulation of cytoskeletal dynamics is required for salivary gland branching morphogenesis: S. Ray, et al.; Mol. Biol. Cell 25, 2393 (2014)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
